Ocular surface disease (OSD) is a prevalent yet frequently underrecognized challenge in the management of glaucoma. A significant overlap between glaucoma and dry eye disease (DED ...
The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to ...
Discussions from the EnVision Summit 2025 highlighted several clinical and surgical challenges that are expected to shape ...
China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...
Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell ...
This finding was based on the results of a study published in BMJ Open Ophthalmology1 that patients with diabetes who were ...
Early safety and visual performance signals were reported at 3 months from a first-in-human (FIH) clinical study evaluating ...
Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...
NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and ...
Edinburgh Biosciences has reported encouraging early outcomes from a structured long-term safety and performance follow-up ...
Department of Ophthalmology at NYU Grossman School of Medicine in New York, New York. NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results